Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Cysteine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.80 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.80 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 2/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteine SCHEMBL1268415 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL902046 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL3320713 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL6675043 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL3320717 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL6028716 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL1907826 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL28436580 | 0.98 | PTGS1 (0.76) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Aspartic Acid SCHEMBL8628354 | 0.91 | PTGS1 (0.67) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Serine SCHEMBL418635 | 0.91 | PTGS1 (0.67) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143844-A1 | NOVEL METHODS FOR PRODUCING PEPTIDE THIOESTER AND PEPTIDE | GLYTECH, INC. (JP) | 2023-05-11 | — | — | US | claimed |
| US-20060189567-A1 | Compound having affinity with calcified tissue | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2006-08-24 | — | — | US | claimed |
| EP-1609797-A1 | COMPOUND HAVING AFFINITY WITH CALCIFIED TISSUE | Nihon Medi-Physics Co., Ltd. (JP) | 2005-12-28 | — | — | EP | claimed |
| EP-4308169-A2 | B-LYMPHOCYTE SPECIFIC AMATOXIN ANTIBODY CONJUGATES | Heidelberg Pharma Research GmbH (DE) | 2024-01-24 | — | — | EP | disclosed |
| US-20230143844-A1 | NOVEL METHODS FOR PRODUCING PEPTIDE THIOESTER AND PEPTIDE | GLYTECH, INC. (JP) | 2023-05-11 | — | — | US | disclosed |
| WO-2022194988-A2 | B-LYMPHOCYTE SPECIFIC AMATOXIN ANTIBODY CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2022-09-22 | — | — | WO | disclosed |
| US-20210322582-A1 | RADIOACTIVE IMIDAZOTHIADIAZOLE DERIVATIVE COMPOUND | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2021-10-21 | — | — | US | disclosed |
| EP-3845541-A1 | RADIOACTIVE IMIDAZOTHIADIAZOLE DERIVATIVE COMPOUND | Nihon Medi-Physics Co., Ltd (JP) | 2021-07-07 | — | — | EP | disclosed |
| EP-3805260-A1 | WATER-SOLUBLE TRANS-MEMBRANE PROTEINS AND METHODS FOR THE PREPARATION AND USE THEREOF | Massachusetts Institute of Technology (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-112638919-A | Radioactive imidazothiadiazole derivative compound | 日本医事物理股份有限公司 | 2021-04-09 | — | — | CN | disclosed |
| EP-3122767-B1 | WATER-SOLUBLE TRANS-MEMBRANE PROTEINS AND METHODS FOR THE PREPARATION AND USE THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-2354153-A2 | Stable peptide mimetic of HIV gp41 fusion intermediate | Merck Sharp & Dohme Corp. (US) | 2011-08-10 | — | — | EP | disclosed |
| US-7811577-B2 | Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity | MERCK SHARP & DOHME CORP. (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1755667-A4 | STABLE PEPTIDE MIMETIC OF HIV GP41 FUSION INTERMEDIATE | MERCK & CO INC (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20070224212-A1 | Stable Peptide Mimetic of Hiv Gp41 Fusion Intermediate | MERCK SHARP & DOHME LLC | 2007-09-27 | — | — | US | disclosed |
| CN-1968710-A | Stable peptide mimetic of HIV gp41 fusion intermediate | MERCK & CO INC (US) | 2007-05-23 | — | — | CN | disclosed |
| EP-1755667-A2 | STABLE PEPTIDE MIMETIC OF HIV GP41 FUSION INTERMEDIATE | Merck & Co., Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20060189567-A1 | Compound having affinity with calcified tissue | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1609797-A1 | COMPOUND HAVING AFFINITY WITH CALCIFIED TISSUE | Nihon Medi-Physics Co., Ltd. (JP) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005118886-A2 | STABLE PEPTIDE MIMETIC OF HIV GP41 FUSION INTERMEDIATE | MERCK & CO., INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322582-A1 | RADIOACTIVE IMIDAZOTHIADIAZOLE DERIVATIVE COMPOUND | CA9, CA4, CA14 | PTGS1 4346/4885SLC7A11 1566/4885GLRA1 1949/4885 |
| US-20230143844-A1 | NOVEL METHODS FOR PRODUCING PEPTIDE THIOESTER AND PEPTIDE | QPCT, PTMS, QPCTL | PTGS1 3503/4885SLC7A11 133/4885GLRA1 314/4885 |
| US-20060189567-A1 | Compound having affinity with calcified tissue | SLC7A1, MBNL1, SHBG | PTGS1 2331/4885SLC7A11 61/4885GLRA1 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.